Division of Viral Hepatitis

Division of Viral Hepatitis
Name	Division of Viral Hepatitis
Formed	19XX
Type	Division
Jurisdiction	United States Department of Health and Human Services
Headquarters	Atlanta, Georgia
Parent agency	Centers for Disease Control and Prevention

Contents

Division of Viral Hepatitis.

The Division of Viral Hepatitis is a specialized public health unit within the Centers for Disease Control and Prevention focused on surveillance, prevention, and control of viral hepatitis pathogens including hepatitis A virus, hepatitis B virus, hepatitis C virus, and related bloodborne infections. It supports clinical guidelines, laboratory science, and population health programs that intersect with agencies such as the Food and Drug Administration, the National Institutes of Health, the World Health Organization, and state health departments in Georgia (U.S. state), California, New York (state), and other U.S. jurisdictions.

Overview

The Division operates as part of federal public health infrastructure alongside entities like the Advisory Committee on Immunization Practices, the Health Resources and Services Administration, the Substance Abuse and Mental Health Services Administration, and academic partners such as Johns Hopkins University, Harvard University, and the University of California, San Francisco. It advances laboratory capacity through collaborations with reference networks including the Association of Public Health Laboratories and supports surveillance systems that inform policy at the Department of Health and Human Services, the White House, and international fora including the United Nations and the Pan American Health Organization.

The Division emerged amid mid‑20th century responses to transfusion‑related hepatitis that engaged institutions such as the National Institutes of Health and leaders like Albert Sabin and Baruch S. Blumberg. Its formation paralleled initiatives like the development of the Recombinant DNA Advisory Committee era and milestones including the licensing of vaccines by the Food and Drug Administration and the approval processes overseen by the United States Congress. Over time the Division’s evolution has reflected events such as the rise of the HIV/AIDS epidemic, the advent of nucleic acid testing promoted by groups like the American Association of Blood Banks, and public health campaigns resembling those of the Centers for Disease Control and Prevention during outbreaks in cities like New Orleans and Seattle.

Organizationally the Division integrates laboratory science, epidemiology, clinical liaison, and health communications units that coordinate with the Occupational Safety and Health Administration, the Department of Veterans Affairs, and municipal health agencies in places like Chicago and Los Angeles. Program portfolios include vaccination strategy linked to the Advisory Committee on Immunization Practices, blood safety programs tied to the American Red Cross, perinatal prevention initiatives informed by the American College of Obstetricians and Gynecologists, and harm‑reduction collaborations with organizations such as Mothers Against Drunk Driving and the Samaritan's Purse model for service delivery. Internal offices maintain relationships with research funders like the Bill & Melinda Gates Foundation, the Robert Wood Johnson Foundation, and federal laboratories including the Walter Reed Army Institute of Research.

The Division deploys surveillance systems that link with national datasets maintained by the National Center for Health Statistics, the Behavioral Risk Factor Surveillance System, and electronic reporting platforms used by state departments in Texas, Florida, and Ohio. Research agendas span molecular virology, vaccine effectiveness, and treatment outcomes in collaboration with the National Institute of Allergy and Infectious Diseases, the Centers for Medicare & Medicaid Services, and international research centers such as the Institut Pasteur and the London School of Hygiene & Tropical Medicine. The Division’s work informs guidelines used by professional bodies including the Infectious Diseases Society of America, the American Medical Association, and the American Public Health Association.

Prevention strategies promoted by the Division include vaccination programs tied to school entry policies in jurisdictions like New Jersey and Massachusetts, screening recommendations for populations served by the Veterans Health Administration and community clinics funded by the Ryan White HIV/AIDS Program, and integration of hepatitis C curative therapies into care models advocated by the World Health Organization and pharmaceutical regulatory reviews at the Food and Drug Administration. Testing initiatives coordinate with commercial laboratories such as Quest Diagnostics and LabCorp and with community organizations including Planned Parenthood and local syringe service programs in cities like San Francisco and Portland, Oregon.

The Division’s partnerships encompass global actors like the World Health Organization, bilateral programs with the United States Agency for International Development, and multilateral initiatives involving the Global Fund to Fight AIDS, Tuberculosis and Malaria. Its impact is reflected in declines in incidence documented alongside vaccination rollouts in countries like Japan, Australia, and United Kingdom, reductions in mother-to-child transmission strategies influenced by agencies such as the Pan American Health Organization, and implementation science collaborations with universities including Columbia University and Yale University. The Division also engages with advocacy groups such as the Hepatitis B Foundation and the Hepatitis C Trust to translate science into policy at venues like the United States Senate and public briefings at the White House.